CoChat
Sign Up
Cited by 562Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Open access
Elman, Michael J., Ayala, Allison, Bressler, Neil M., Browning, David, Flaxel, Christina J., Glassman, Adam R., Jampol, Lee M., Stone, Thomas W.·2015·Ophthalmology
DOI 10.1016/j.ophtha.2014.08.047PMC PMC4520307
Open this paper in CoChat — free account

Abstract

Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks) focal/grid laser treatment for diabetic macular edema (DME).Design Multicenter, randomized clinical trial.Participants Among participants from the trial with 3 years of follow-up who subsequently consented to a 2-year extension and survived through 5 years, 124 (97%) and 111 (92%) completed the 5-year visit in the prompt and deferred groups, respectively.Methods Random assignment to ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and prompt or deferred (≥24 weeks) focal/grid laser treatment.Main outcome measures Best-corrected visual acuity at the 5-year visit.Results The mean change in visual acuity letter score from baseline to the 5-year visit was +7.2 letters in the prompt laser group compared with +9.8 letters in the deferred laser group (mean difference, -2.6 letters; 95% confidence interval, -5.5 to +0.4 letters; P = 0.09). At the 5-year visit in the prompt versus deferred laser groups, there was vision loss of ≥10 letters in 9% versus 8%, an improvement of ≥10 letters in 46% versus 58%, and an improvement of ≥15 letters in 27% versus 38% of participants, respectively. From baseline to 5 years, 56% of participants in the deferred group did not receive laser. The median number of injections was 13 versus 17 in the prompt and deferral groups, including 54% and 45% receiving no injections during year 4 and 62% and 52% receiving no injections during year 5, respectively.Conclusions Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2014.08.047

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 10 references

1 of the 10 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 401–500 of 560

Related

See all

Metadata

Authors
Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W.
Affiliations
  • Elman Retina Group (US)
  • Jaeb Center for Health Research (US)
  • Johns Hopkins University (US)
  • Charlotte Eye Ear Nose & Throat Associates (US)
  • Northwestern University (US)
  • Retina Associates of Kentucky (US)
Corresponding author
Ayala, Allison
ORCID
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2015-02
Volume
122
Issue
2
Pages
375-381
ISSN
0161-6420 (ISSN-L)
DOI
10.1016/j.ophtha.2014.08.047
PMC
PMC4520307
OpenAlex
W1980342089
Cited by
562
References
10
Citations by year
2026: 8 · 2025: 18 · 2024: 22 · 2023: 20 · 2022: 35 · 2021: 39 · 2020: 55 · 2019: 41 · 2018: 45 · 2017: 79 · 2016: 72 · 2015: 73
FWCI
79.09
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Eye Institute (EY14231, EY-14229, EY18817, EY023207, U10EY018817, U10EY014229, U10EY023207, U10EY014231, UG1EY014231)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
diabetic macular edema, ranibizumab, intravitreal injection, best-corrected visual acuity, long-term visual outcomes, anti-VEGF therapy, vision loss, treatment duration extension, retinal laser treatment, anti-angiogenic therapy, treatment burden reduction
MeSH terms
Ranibizumab, Aged, Combined Modality Therapy, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Visual Acuity, Treatment Outcome, Laser Coagulation, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review